Aviva PLC Relmada Therapeutics, Inc. Transaction History

Aviva PLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 13, 2021	SELL	$31.52 - $39.28 $1.06 Million - $1.32 Million	-33,559 Closed	0 $0
Q4 2020 Feb 10, 2021	SELL	$29.88 - $39.8 $812,915 - $1.08 Million	-27,206 Reduced 44.77%	33,559 $1.08 Million
Q3 2020 Nov 12, 2020	BUY	$34.42 - $43.78 $2.09 Million - $2.66 Million	60,765 New	60,765 $2.29 Million

8.32M

364K

46.5K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $8.58M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

Stay updated on Aviva PLC with notifications on news.